URANIUM ROYALTY CORP (UROY) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:UROY • CA91702V1013

3.925 USD
+0.17 (+4.39%)
Last: Feb 6, 2026, 03:34 PM
Fundamental Rating

2

UROY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 207 industry peers in the Oil, Gas & Consumable Fuels industry. No worries on liquidiy or solvency for UROY as it has an excellent financial health rating, but there are worries on the profitability. UROY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • UROY had negative earnings in the past year.
  • In the past year UROY had a positive cash flow from operations.
  • In the past 5 years UROY reported 4 times negative net income.
  • UROY had a negative operating cash flow in each of the past 5 years.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • UROY's Return On Assets of 0.15% is on the low side compared to the rest of the industry. UROY is outperformed by 68.12% of its industry peers.
  • With a Return On Equity value of 0.15%, UROY is not doing good in the industry: 67.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA 0.15%
ROE 0.15%
ROIC N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

  • UROY's Profit Margin of 1.35% is on the low side compared to the rest of the industry. UROY is outperformed by 62.32% of its industry peers.
  • UROY has a worse Gross Margin (15.75%) than 67.63% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1.35%
GM 15.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • UROY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for UROY has been increased compared to 1 year ago.
  • The number of shares outstanding for UROY has been increased compared to 5 years ago.
  • UROY has a worse debt/assets ratio than last year.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • UROY has an Altman-Z score of 375.85. This indicates that UROY is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 375.85, UROY belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • The Debt to FCF ratio of UROY is 0.01, which is an excellent value as it means it would take UROY, only 0.01 years of fcf income to pay off all of its debts.
  • UROY's Debt to FCF ratio of 0.01 is amongst the best of the industry. UROY outperforms 90.82% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that UROY is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.00, UROY belongs to the top of the industry, outperforming 83.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Altman-Z 375.85
ROIC/WACCN/A
WACC8.09%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • UROY has a Current Ratio of 265.74. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
  • UROY has a Current ratio of 265.74. This is amongst the best in the industry. UROY outperforms 100.00% of its industry peers.
  • UROY has a Quick Ratio of 80.66. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of UROY (80.66) is better than 99.52% of its industry peers.
Industry RankSector Rank
Current Ratio 265.74
Quick Ratio 80.66
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for UROY have decreased strongly by -93.40% in the last year.
  • UROY shows a decrease in Revenue. In the last year, the revenue decreased by -0.90%.
EPS 1Y (TTM)-93.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-0.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.62%

3.2 Future

  • UROY is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -129.02% yearly.
  • Based on estimates for the next years, UROY will show a very negative growth in Revenue. The Revenue will decrease by -37.84% on average per year.
EPS Next Y600.6%
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%
EPS Next 5YN/A
Revenue Next Year248.23%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M 50M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • UROY is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • UROY's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 26.24
EV/EBITDA N/A
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as UROY's earnings are expected to decrease with -129.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • UROY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

URANIUM ROYALTY CORP

NASDAQ:UROY (2/6/2026, 3:34:10 PM)

3.925

+0.17 (+4.39%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)12-11
Earnings (Next)03-04
Inst Owners28.61%
Inst Owner Change-8.36%
Ins Owners2.09%
Ins Owner ChangeN/A
Market Cap548.32M
Revenue(TTM)37.95M
Net Income(TTM)512.00K
Analysts75
Price Target3.93 (0.13%)
Short Float %5.32%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.72%
PT rev (3m)2.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.77
P/FCF 26.24
P/OCF 25.32
P/B 2.27
P/tB 2.27
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)0.15
FCFY3.81%
OCF(TTM)0.16
OCFY3.95%
SpS0.2
BVpS1.73
TBVpS1.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.15%
ROE 0.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.35%
GM 15.75%
FCFM 75.35%
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.01
Debt/EBITDA N/A
Cap/Depr 644.44%
Cap/Sales 2.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 5583.98%
Current Ratio 265.74
Quick Ratio 80.66
Altman-Z 375.85
F-Score5
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y600.6%
EPS Next 2Y-145.07%
EPS Next 3Y-129.02%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.9%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-99.62%
Revenue Next Year248.23%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.84%
Revenue Next 5YN/A
EBIT growth 1Y-154.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year142.68%
EBIT Next 3Y3.56%
EBIT Next 5YN/A
FCF growth 1Y234.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y239.06%
OCF growth 3YN/A
OCF growth 5YN/A

URANIUM ROYALTY CORP / UROY FAQ

What is the fundamental rating for UROY stock?

ChartMill assigns a fundamental rating of 2 / 10 to UROY.


Can you provide the valuation status for URANIUM ROYALTY CORP?

ChartMill assigns a valuation rating of 1 / 10 to URANIUM ROYALTY CORP (UROY). This can be considered as Overvalued.


How profitable is URANIUM ROYALTY CORP (UROY) stock?

URANIUM ROYALTY CORP (UROY) has a profitability rating of 0 / 10.


What is the financial health of URANIUM ROYALTY CORP (UROY) stock?

The financial health rating of URANIUM ROYALTY CORP (UROY) is 8 / 10.